Off the Scales - by Aimee Donnellan (Hardcover)

Book Synopsis

The inside story of the race to develop Ozempic, and its potentially revolutionary impact on public health and culture.

A "cure" for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates hormones in the stomach, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries--from health care to fast food to fashion--and it has quickly made its creator, Denmark's Novo Nordisk, the most valuable company in Europe. But the impact of these drugs goes far beyond billion dollar profits; a true long-term cure for obesity could save 40% of American adults from dangerous preventable illnesses. And as their success continues to grow, one question looms in the minds of investors, healthcare workers and politicians: are they too good to be true?

In Off the Scales, Reuters journalist Aimee Donnellan illuminates the history of the latest medical breakthrough that is poised to change the world, while bringing difficult social questions about inequality and morality to the forefront. Through original reporting and rigorous research, she forecasts the future of Ozempic and similar medications--and examines what their explosive popularity tells us about our ideals of beauty, the lengths to which people will go in order to become thin, the current state of healthcare, and the inner workings of the pharmaceutical industry.

Along the way, Donnellan profiles the scientist who first discovered GLP-1 and her fight for recognition while her colleagues were thrust into the limelight, and offers new insights into the ways that the food and beauty industries made billions while promoting unhealthy and unrealistic body image standards and accelerating the obesity crisis. She also reveals the lengths that the celebrity class went to obtain this medication when supplies were limited and prescriptions were costly, and relates the firsthand accounts of several early Ozempic users and the transformative effect the drug has had on their weight loss journeys. Above all, Off the Scales is an informative and entertaining study of the unexpected social consequences of finally getting what we've wanted for so long.

About the Author

AIMEE DONNELLAN is a columnist at Reuters, where her reporting has focused on the pharmaceutical, airline, and insurance industries since 2017. Previously she was the Sunday Times banking correspondent, and covered the bond market for the International Financing Review. She holds degrees in English and History from the University of Ireland, Galway, and in journalism from the London School of Journalism. She lives in Dublin with her wife and two children. Off the Scales is her first book.